Quantum-Powered vaccine takes on endometrial cancer
NCT ID NCT07316361
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a personalized vaccine made from each patient's unique cancer mutations. The vaccine is designed to train the immune system to attack the cancer. Forty people with high-risk or recurrent endometrial cancer will receive the vaccine along with standard treatments. The main goals are to see if the vaccine is safe and if it can be made quickly enough for each patient.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized neoantigen peptide vaccine (GYNORYLAQ-TM)
What this could lead to
If successful, this could point toward a new personalized vaccine approach to help the immune system fight endometrial cancer.
What could go wrong
This is a very early, small trial (40 people) focused on safety and feasibility. The vaccine is custom-made for each patient, which is complex and may not work for everyone. It is combined with standard treatments, so any benefit from the vaccine alone is unclear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Biogenea Pharmaceuticals Ltd & Interbalkan Medical Center - International Oncology Center
Thessaloniki, Thessaloniki, 54622, Greece